Clinical Trial

Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

Name: Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer — clinical trial record (NCT07624201)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.

Trial Details

NCT Number	NCT07624201
Lead Sponsor	Harbin Medical University Collaborators: The Fourth Affiliated Hospital of China Medical University, Jilin Provincial Tumor Hospital, Tianjin Medical University Second Hospital, First Hospital of China Medical University
Conditions	Muscle-Invasive Bladder Cancer (MIBC)
Enrollment	58 participants
Start Date	2026-06-01
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-06-03